Shanghai Pharmaceuticals Holding Co., Ltd — CureCurrent

Published trials17

Recruiting shown3

Roles2

SourceClinicalTrials.gov

Clinical trials

17 shown

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.NCT05872347 · lead sponsor · 2023-09-19

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerNCT05860465 · lead sponsor · 2023-09-08

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast CancerNCT05744687 · lead sponsor · 2023-04-24

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney DiseaseNCT05593575 · lead sponsor · 2023-03-22

Study on Human Mass Balance of SPH3127 TabletsNCT05593562 · lead sponsor · 2022-10-16

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential HypertensionNCT05359068 · lead sponsor · 2021-06-10

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS PatientsNCT04084444 · lead sponsor · 2019-12-25

B002 in Patients With HER2-positive Breast CancerNCT04382352 · lead sponsor · 2019-05-28

B003 in Patients With HER2-positive Recurrent or Metastatic Breast CancerNCT03953833 · lead sponsor · 2019-04-01

Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension PatientsNCT03756103 · lead sponsor · 2019-01-11

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy PeopleNCT03255993 · lead sponsor · 2017-10-23

The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health SubjectsNCT03249753 · lead sponsor · 2017-09-23

Phase I Study of SPH1188-11 in NSCLCNCT03231475 · lead sponsor · 2017-07-21

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy VolunteersNCT03128138 · lead sponsor · 2016-12-01

Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateNCT02202395 · lead sponsor · 2014-06-01

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerNCT05555706 · collaborator · 2022-12-06

Optimal MTX Dose With Folic Acid Randomized Case-control TrialNCT04066803 · collaborator · 2018-08-01

Sponsor roles

lead sponsor15

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.